Cenra Inc. (3716.TW) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan

Price
33.45 TWD
Market cap
4.89 bn TWD
P/E (2025)
16.29
P/S (2025)
0.57
Dividend yield
3.00 %
Net margin
3.50 %
Return on equity (ROE)
3.96 %
Return on assets (ROA)
2.41 %

Cenra Inc. financials

Fiscal year20242025
Revenue8.92 bn TWD8.57 bn TWD
Gross profit3.41 bn TWD3.32 bn TWD
Operating income298.91 m TWD428.14 m TWD
EBIT450.13 m TWD480.93 m TWD
Net income317.35 m TWD300.07 m TWD
Diluted EPS – continuing operations2.13 TWD2.05 TWD

Full history since 2002, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Cenra Inc.

Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. It provides CDMO services for internal and external partners; oral solids, injectables, specialty formulations, and APIs, supported by process development, scale-up, and regulatory support; oral solids, injectables, specialty formulations, and high-purity active pharmaceutical ingredients (APIs), supported by process development, scale-up, and regulatory support; distribution, and marketing for prescription drugs, OTC products, health supplements, personal care products, and medical devices;home care, caregiver training, and consulting for elderly support; develops and manufactures veterinary pharmaceuticals, and animal health products for livestock and companion animals and offers CDMO services for animal health partners. Cenra Inc. was founded in 2024 and is headquartered in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.